Top

Reactions Weekly

Published in:

01-07-2023 | Acalabrutinib | Case report

Acalabrutinib

Purpura and plaque formation of the extremities: case report

Published in: Reactions Weekly | Issue 1/2023

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Coban S, et al. DERMATOLOGIC TOXICITY OF A NEW TYROSINE KINASE INHIBITOR IN AN OLDER PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Journal of the American Geriatrics Society 71 (Suppl. 1): S19, Apr 2023. Available from: URL: http://doi.org/10.1111/jgs.18336 [abstract]

Title: Acalabrutinib
Purpura and plaque formation of the extremities: case report
Publication date: 01-07-2023
Publisher: Springer International Publishing
Keywords: Acalabrutinib
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Sarcoidosis
Sarcoidosis
Venous Thrombosis
Venous Thrombosis
Published in: Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-42572-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Acalabrutinib

Purpura and plaque formation of the extremities: case report

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2023

EMA publishes report on ensuring safety of COVID-19 vaccines

Amphotericin-b

Safety of SGLT2 inhibitors in elderly patients with diabetic kidney disease

Hydrocortisone/remdesivir

Tozinameran

Antineoplastics